Genetic Signatures Ltd
ASX:GSS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.405
0.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genetic Signatures Ltd
Gross Margin
Genetic Signatures Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | AU |
| Market Cap | 150.7m AUD |
| Gross Margin |
45%
|
| Country | US |
| Market Cap | 1.3T USD |
| Gross Margin |
55%
|
| Country | US |
| Market Cap | 196.3B USD |
| Gross Margin |
41%
|
| Country | US |
| Market Cap | 170.3B USD |
| Gross Margin |
60%
|
| Country | KR |
| Market Cap | 66.5T KRW |
| Gross Margin |
50%
|
| Country | CH |
| Market Cap | 37.6B CHF |
| Gross Margin |
29%
|
| Country | US |
| Market Cap | 38.5B USD |
| Gross Margin |
55%
|
| Country | US |
| Market Cap | 36.7B USD |
| Gross Margin |
35%
|
| Country | US |
| Market Cap | 26.4B USD |
| Gross Margin |
59%
|
| Country | US |
| Market Cap | 23B USD |
| Gross Margin |
35%
|
| Country | US |
| Market Cap | 22.3B USD |
| Gross Margin |
64%
|
Genetic Signatures Ltd
Glance View
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Genetic Signatures Ltd's most recent financial statements, the company has Gross Margin of 44.6%.
You don't have any saved screeners yet
